In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures the Epidiolex. The drug is expected to cost between $2500 to $500 for a monthly supply.
An FDA advisory panel unanimously recommended in April that Epidiolex be approved for use in the United States.